Development and Validation of a Discriminative Dissolution Test for Betamethasone Sodium Phosphate and Betamethasone Dipropionate Intramuscular Injectable Suspension
- 987 Downloads
The intramuscular administration of the injectable suspension betamethasone sodium phosphate (BSP) and betamethasone dipropionate (BD) has immediate therapeutic activity due to solubilized BSP and prolonged activity resulting from the slow release of BD micro-crystals. The purpose of this study was to develop and validate a dissolution method for BD in intramuscular injectable suspensions with detection by high-performance liquid chromatography (HPLC) method. Five commercial products presented a distribution of particle sizes, ranging between 7.43 and 40.25 μm as measured by laser diffraction. It was also found that particle sizes differed between batches of the same product. The different products were tested using the paddle apparatus, with stirring speeds of 25 and 50 rpm in 300 mL of phosphate buffer; simulated body fluid, muscle fluid, and synovial fluid were used as biorelevant dissolution media at 37 ± 0.5°C. It was verified that not only does average particle size affect the dissolution rate, but also the mode and the polydispersity index of the particles. Discriminatory power was obtained using the in vitro dissolution method with 0.1 M sodium phosphate buffer pH 7.4 containing 0.1% sodium lauryl sulfate and a stirring speed of 50 rpm. The HPLC-method is linear, precise, selective, and accurate for the quantification of BSP and BD in dissolution profile testing. This dissolution method can be utilized as a method to control the quality of these injectable suspensions.
Key wordsdipropionate betamethasone dissolution test intramuscular injectable suspensions simulated muscular fluid sodium phosphate betamethasone
This work was supported by FAPERJ, Edital CAPES Nanobiotecnologia 2008, and CNPq. We are grateful to Michelle Parvatiyar for her English review.
- 1.Diprospan® bull. Mantecorp Indústria Química e Farmacêutica LTDA, Rio de Janeiro; 2012. http://www4.anvisa.gov.br/base/visadoc/BM/BM[27314-1-0].PDF. Accessed 10 Sept 2012.
- 9.The United States Pharmacopoeia–National Formulary. <711 > Dissolution. 34th ed, Rockville, MD: USP Convention Inc.; 2011Google Scholar
- 17.The United States Pharmacopoeia–National Formulary 29. <1092 > The dissolution procedure: development and validation. 34th ed, Rockville, MD: USP Convention Inc.; 2011.Google Scholar
- 19.ICH, validation of analytical procedures: text and methodology (Q2R1), in International Conference on Harmonization; November 2005.Google Scholar
- 20.Shabir GA. Validation of high-performance liquid chromatography methods for pharmaceutical analysis: understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. J Chromatogr A. 2003;987:57–66. doi: 10.1016/S0021-9673(02)01536-4.CrossRefPubMedGoogle Scholar
- 22.Lindenberg M, Wiegand C, Dressman JB. Comparison of the adsorption of several drugs to typical filter materials. Dissolution Technol. 2005;12:22–5.Google Scholar
- 25.Marques MRC, Loebenberg R, Almukainzi M. Simulated biological fluids with possible application in dissolution testing. Dissolution Technol. 2011;18:15–28.Google Scholar
- 29.FDA. Guidance for industry: dissolution testing of immediate release solid oral dosage forms. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER); August 1997.Google Scholar
- 33.R. M. Patel. Parenteral suspension: an overview. Int J Curr Pharm Res. 2010;2,3:3–13.Google Scholar
- 34.The United States Pharmacopoeia, National Formulary 29. 34th ed., Supp. 1. Rockville, MD: U.S. Pharmacopoeial Convention; 2011.Google Scholar